Meeting
2014 ASCO Annual Meeting
Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.
Authors
Katrina H. Smith
Dana-Farber Cancer Institute, Boston, MA
Katrina H. Smith , Eudocia Quant Lee , Alona Muzikansky , Elizabeth Robins Gerstner , Dan G. Duda , David A. Reardon , Lakshmi Nayak , Andrew David Norden , Lisa M. Doherty , Jennifer Rifenburg , Debra C. LaFrankie , Sandra Ruland , Julee Pulverenti , Deirdre Stokes , Priscilla Lam , Christine Sceppa McCluskey , Sarah C. Gaffey , Tracy Batchelor , Rakesh K. Jain , Patrick Y. Wen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01339039
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2031)
DOI
10.1200/jco.2014.32.15_suppl.2031
Abstract #
2031
Poster Bd #
22
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.
First Author: Eudocia Quant Lee
Poster
2023 ASCO Annual Meeting
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.
First Author: Dinu Stefan
Poster
2019 ASCO Annual Meeting
Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.
First Author: Michael Lim
Poster
2018 ASCO Annual Meeting
Hypofractionnated stereotactic radiotherapy and anti-PDL1 durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial.
First Author: Damien Pouessel